Table 2 Antisense LncRNAs are related to drug resistance in cancer

HOXD-AS1

Cervical cancer

Cisplatin

HOXD-AS1 enhances chemoresistance of cisplatin-resistant cancer cells by modulating miR-130a-3p/ZEB1 axis

[142]

DLX6-AS1

Breast cancer

DLX6-AS1 promotes cisplatin resistance through miR-199b-5p/PXN signaling

[143]

NCK1-AS1

Osteosarcoma

NCK1-AS1 knockdown enhances Cisplatin sensitivity of cancer cells by regulating miR-137

[144]

SLC7A11-AS1

Pancreatic cancer

Gemcitabine

SLC7A11-AS1 promotes Gemcitabine-resistance by Blocking SCF β-TRCP-Mediated Degradation of NRF2

[145]

SBF2-AS1

Pancreatic cancer

SBF2-AS1 promotes the expression of TWF1 by binding with miR-142-3p to induce gemcitabine resistance

[146]

LOXL1-AS1

Prostate cancer

Doxorubicin

LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance

[147]

FOXC2-AS1

Osteosarcoma

FOXC2-AS1 promotes doxorubicin resistance by increasing the expression of FOXC2

[148]

AFAP1-AS1

Breast cancer

Trastuzumab

AFAP1-AS1 promotes trastuzumab resistance by binding with AUF1 and activating ERBB2 expression

[149]

SBF2-AS1

Glioblastoma

Temozolomide

SBF2-AS1 enhances chemoresistance to temozolomide by functioning as a ceRNA for miR-151a-3p

[150]

ADAMTS9-AS2

Glioblastoma

ADAMTS9-AS2 promotes Temozolomide Resistance via Upregulating the FUS/MDM2 Ubiquitination Axis

[151]

NR2F1-AS1

Liver cancer

Oxaliplatin

NR2F1-AS1 regulates oxaliplatin resistance by targeting ABCC1 via miR-363

[152]

DSCAM-AS1

Breast cancer

Tamoxifen

DSCAM-AS1 enhances Tamoxifen resistance by functioning as a sponge of miR-137

[153]

ADAMTS9-AS2

Breast cancer

ADAMTS9-AS2 enhances tamoxifen resistance by activating miR-130a-5p

[154]

AFAP1-AS1

Prostate cancer

Paclitaxel

AFAP1-AS1 modulates the sensitivity of paclitaxel via miR-195-5p/FKBP1A axis

[155]

DDX11-AS1

Esophageal cancer

DDX11-AS1 promotes resistance cancer cells to Paclitaxel by inhibiting TOP2A expression via TAF1

[156]